Does high SHBG lower free testosterone and androgen signaling?

Sex hormone-binding globulin (SHBG), a liver-derived glycoprotein, serves as a primary regulator of androgen bioavailability. For women navigating midlife changes, understanding how SHBG influences tissue-level androgen signaling is crucial for maintaining musculoskeletal and metabolic health.

Physiological mechanisms and bioavailability

• High-affinity binding: SHBG binds circulating testosterone with high affinity, while a smaller portion binds weakly to albumin. When SHBG levels rise, a larger share of circulating testosterone is bound, directly lowering the concentration of unbound, free testosterone.
• The free hormone hypothesis: Only the free and weakly bound (bioavailable) fractions of testosterone can diffuse across cell membranes to bind and activate classical nuclear androgen receptors. Consequently, elevated SHBG restricts the intracellular pool of testosterone available for genomic signaling, even if total testosterone levels appear normal.

Tissue-level and emerging signaling effects

• Musculoskeletal implications: Reduced tissue-available androgen signaling has direct physiological consequences. In postmenopausal women, higher SHBG levels and the resulting drop in bioavailable testosterone are consistently associated with lower muscle mass.
• Non-genomic signaling: Beyond its role as a passive carrier, emerging evidence indicates that SHBG can bind directly to specific cell membrane receptors. This interaction triggers receptor-mediated, non-genomic signaling cascades upon binding sex steroids, adding a layer of regulatory complexity to cellular hormone response.

Bottom line

• High SHBG levels lower free testosterone and reduce bioavailable androgen signaling at the tissue level, which is directly associated with reduced muscle mass and altered cellular signaling in postmenopausal women.